Konstantinos Papamichael1, Adam S Cheifetz. 1. Division of Gastroenterology, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The current review provides an updated overview on the role of therapeutic drug monitoring (TDM) of biological therapies in inflammatory bowel disease (IBD). We examine the data behind TDM for the antitumor necrosis factor agents, vedolizumab and ustekinumab, in patients with IBD. In addition, we discuss reactive vs. proactive TDM. RECENT FINDINGS: There is a positive correlation between biologic drug concentrations and favorable therapeutic outcomes in IBD, although the majority of data refer to antitumor necrosis factor therapy. Reactive TDM has rationalized the management of patients with IBD with loss of response to biological therapy. Moreover, reactive TDM of infliximab has been proven to be more cost-effective when compared with empiric dose optimization. Preliminary data suggest that proactive TDM of infliximab and adalimumab applied in patients with clinical response/remission is associated with better therapeutic outcomes compared with standard of care (empiric treatment and/or reactive TDM). SUMMARY: For all biologics in IBD, there is a positive correlation between drug concentrations and favorable therapeutic outcomes. Reactive TDM is the new standard of care for optimizing biologic therapies in IBD, whereas recent data suggest an important role of proactive TDM for optimizing antitumor necrosis factor therapy in IBD.
PURPOSE OF REVIEW: The current review provides an updated overview on the role of therapeutic drug monitoring (TDM) of biological therapies in inflammatory bowel disease (IBD). We examine the data behind TDM for the antitumor necrosis factor agents, vedolizumab and ustekinumab, in patients with IBD. In addition, we discuss reactive vs. proactive TDM. RECENT FINDINGS: There is a positive correlation between biologic drug concentrations and favorable therapeutic outcomes in IBD, although the majority of data refer to antitumor necrosis factor therapy. Reactive TDM has rationalized the management of patients with IBD with loss of response to biological therapy. Moreover, reactive TDM of infliximab has been proven to be more cost-effective when compared with empiric dose optimization. Preliminary data suggest that proactive TDM of infliximab and adalimumab applied in patients with clinical response/remission is associated with better therapeutic outcomes compared with standard of care (empiric treatment and/or reactive TDM). SUMMARY: For all biologics in IBD, there is a positive correlation between drug concentrations and favorable therapeutic outcomes. Reactive TDM is the new standard of care for optimizing biologic therapies in IBD, whereas recent data suggest an important role of proactive TDM for optimizing antitumor necrosis factor therapy in IBD.
Authors: Geert D'Haens; Severine Vermeire; Guy Lambrecht; Filip Baert; Peter Bossuyt; Benjamin Pariente; Anthony Buisson; Yoram Bouhnik; Jérôme Filippi; Janneke Vander Woude; Philippe Van Hootegem; Jacques Moreau; Edouard Louis; Denis Franchimont; Martine De Vos; Fazia Mana; Laurent Peyrin-Biroulet; Hedia Brixi; Matthieu Allez; Philip Caenepeel; Alexandre Aubourg; Bas Oldenburg; Marieke Pierik; Ann Gils; Sylvie Chevret; David Laharie Journal: Gastroenterology Date: 2018-01-06 Impact factor: 22.682
Authors: M G Ward; B Warner; N Unsworth; S-W Chuah; C Brownclarke; S Shieh; M Parkes; J D Sanderson; Z Arkir; J Reynolds; P R Gibson; P M Irving Journal: Aliment Pharmacol Ther Date: 2017-05-08 Impact factor: 8.171
Authors: Omoniyi J Adedokun; William J Sandborn; Brian G Feagan; Paul Rutgeerts; Zhenhua Xu; Colleen W Marano; Jewel Johanns; Honghui Zhou; Hugh M Davis; Freddy Cornillie; Walter Reinisch Journal: Gastroenterology Date: 2014-08-28 Impact factor: 22.682
Authors: Freddy Cornillie; Stephen B Hanauer; Robert H Diamond; Jianping Wang; Kezhen L Tang; Zhenhua Xu; Paul Rutgeerts; Séverine Vermeire Journal: Gut Date: 2014-01-28 Impact factor: 23.059
Authors: H Nakase; S Motoya; T Matsumoto; K Watanabe; T Hisamatsu; N Yoshimura; T Ishida; S Kato; T Nakagawa; M Esaki; M Nagahori; T Matsui; Y Naito; T Kanai; Y Suzuki; M Nojima; M Watanabe; T Hibi Journal: Aliment Pharmacol Ther Date: 2017-09-08 Impact factor: 8.171
Authors: Mark T Osterman; Maria Rosario; Karen Lasch; Morris Barocas; Jayson D Wilbur; Nathanael L Dirks; Marc R Gastonguay Journal: Aliment Pharmacol Ther Date: 2019-01-20 Impact factor: 8.171
Authors: Konstantinos Papamichael; Niels Vande Casteele; Jenny Jeyarajah; Vipul Jairath; Mark T Osterman; Adam S Cheifetz Journal: Am J Gastroenterol Date: 2021-05-01 Impact factor: 12.045